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Background—Plasma concentrations of natriuretic peptides (NPs) are associated with morbidity and mortality in patients
with systolic heart failure (HF). However, the role of NP as a prognostic marker in patients with HF and preserved
ejection fraction (HFpEF) has not been studied in a large cohort of well-characterized patients. Moreover, it is unclear
whether treatments have a differential effect on morbidity and mortality across the spectrum of NP levels.
Methods and Results—N-terminal pro-brain natriuretic peptide (NT-proBNP) was measured at baseline in 3480 patients in the
I-PRESERVE (Irbesartan in Heart Failure with Preserved Ejection Fraction Trial). In a multivariable Cox regression model,
NT-proBNP above the median of 339 pg/mL was independently associated with an increased risk of the primary end point
of all-cause mortality and prespecified cardiovascular hospitalizations (adjusted hazard ratio [HR], 1.79; 95% CI, 1.56 to 2.10;
P0.001); all-cause mortality (adjusted HR, 2.04; 95% CI, 1.68 to 2.47; P0.001); and a composite of HF events, including
death due to worsening HF or sudden death or hospitalization due to worsening HF (adjusted HR, 1.77; 95% CI, 1.43 to 2.20;
P0.001). There were significant interactions between the effect of irbesartan and median split of baseline NT-proBNP for
the primary outcome (P0.005), all-cause mortality (P0.05), and the HF composite outcome (P0.001). Use of irbesartan
was associated with improved outcomes in patients with NT-proBNP below, but not above, the median. After adjusting for
20 baseline covariates, irbesartan still had a beneficial effect on the primary outcome (HR, 0.74; 95% CI, 0.60 to 90;
P0.003), all-cause mortality (HR, 0.75; 95% CI, 0.56 to 0.99; P0.046), and HF composite outcome (HR, 0.57; 95% CI,
0.41 to 0.80; P0.001) in patients with NT-proBNP below the median.
Conclusions—The unexpected benefit of irbesartan in lower-risk patients with HFpEF in this post hoc analysis may indicate effects
on early, but not later, high-risk stages of the disease. These findings question the strategy of using elevated plasma concentrations
of NP as a patient selection criterion in HFpEF trials. More studies are needed to support or contest this practice.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00095238.
(Circ Heart Fail. 2011;4:569-577.)
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Higher levels of natriuretic peptides have been indepen-dently associated with mortality and morbidity in pa-
tients with heart failure (HF) and reduced ejection fraction
(HFrEF).1,2 Data on natriuretic peptide level as a prognostic
marker in patients with HF and preserved EF (HFpEF) are
limited and suggest that higher plasma concentrations of
natriuretic peptides are associated with an increased likeli-
hood of morbid and fatal events.3–6 Recently, HF clinical
trials have begun to exclude patients with low concentrations
of plasma natriuretic peptides to increase the likelihood that the
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patients being enrolled have HF and to increase the number of
outcome events and, presumably, statistical power.7–11 This
approach to patient selection assumes that the study interven-
tion will have a similar or even greater effect in the higher-
risk patients, but this presumption is not well established.12–15
Indeed, a recent post hoc analysis of CORONA (Controlled
Rosuvastatin Multinational Trial in Heart Failure) showed
that patients in the lowest tertile of plasma N-terminal
pro-brain natriuretic peptide (NT-proBNP) had greater bene-
fit from rosuvastatin compared with patients in higher ter-
tiles.15 Higher plasma NT-proBNP concentrations may iden-
tify patients with more advanced HF that is refractory to the
benefits of a particular therapy. Post hoc analyses of data
from the Irbesartan in Heart Failure with Preserved Ejection
Fraction Trial (I-PRESERVE) were conducted to explore the
relationship of baseline measurements of NT-proBNP with
prognosis and to test for interactions with the effects of the
angiotensin receptor blocker irbesartan.
Editorial see p 538
Clinical Perspective on p 577
Methods
Study Design and Patient Selection
I-PRESERVE was a randomized, placebo-controlled, double-blind,
multicenter trial that enrolled 4128 men and women with symptom-
atic HFpEF to evaluate the efficacy of the angiotensin receptor
blocker irbesartan.16 Briefly, patients aged 60 years with symp-
tomatic (New York Heart Association class II to IV) HF, a left
ventricular (LV) EF 45%, and at least 1 hospitalization for HF
during the previous 6 months were eligible for enrollment. Patients
who had not been hospitalized were required to have ongoing class
III or IV symptoms with corroborative evidence of HF or a likely
substrate for HFpEF, such as electrocardiographic or echocardio-
graphic evidence of LV hypertrophy or, if atrial fibrillation was
absent, left atrial enlargement. The primary end point was the
composite of all-cause mortality and protocol-specified cardiovascu-
lar hospitalizations (HF, myocardial infarction, stroke, ventricular or
atrial arrhythmias). The secondary end points were (1) all-cause
mortality and (2) the composite of HF death or hospitalization.
Deaths and hospitalizations were adjudicated by a blinded indepen-
dent end point committee, using prespecified criteria.
NT-proBNP and Other Measurements
Plasma NT-proBNP was measured at baseline in 3480 (84%) of the
4128 patients. The baseline characteristics of patients with NT-
proBNP measurements included in this analysis were not different
from all the patients randomized in the study, as shown in a previous
publication.17 Plasma samples drawn at baseline were stored at
20°C, and NT-proBNP was measured using Elecsys 2010 (Roche
Diagnostic; Basel, Switzerland) in a central laboratory (LabCorp
Belgium). Several other laboratory variables, such as hemoglobin,
serum albumin, electrolyte, and creatinine levels, also were mea-
sured at baseline. Estimated glomerular filtration rate was calculated
using the Modification of Diet in Renal Disease equation.18 The
large number of other baseline variables and their relationships to
plasma NT-proBNP in the I-PRESERVE cohort have been reported
previously.17 The presence of atrial fibrillation, estimated glomerular
filtration rate, and age were the strongest correlates of baseline
NT-proBNP.
Data Analysis
First, the relationship between the natural logarithm of the skewed
distribution of baseline levels of NT-proBNP were entered into Cox
regression models along with several other baseline assessments to
confirm that NT-proBNP was independently associated with the
study end points. Indicator variables representing the quartiles of the
baseline NT-proBNP levels also were analyzed to examine the trend
in estimates of the natural logarithm of the hazard ratio (HR), the
dependent variable in Cox models. Testing for interactions with
treatment is greatly simplified by a 2-way split of subjects, and
statistical power is enhanced by analysis of larger subgroups with
extreme differences.19 Furthermore, in practice, patients often are
split into only a few prognostic groups that are treated differently, or
a single threshold value is set for enrollment of subjects into clinical
trials. Because there are no predefined thresholds of NT-proBNP for
selecting patients who might benefit more or less from treatment
with an angiotensin II receptor blocker, analyses were done by
arbitrarily splitting the sample, using the median NT-proBNP, into 2
risk groups. Recognizing that the median in this sample is not
necessarily the most informative threshold for using NT-proBNP to
select patients for a clinical trial and the potential loss of information
when using a dichotomous split rather than a continuous measure,
the median split of NT-proBNP was entered into Cox regression
models to at least be assured that this particular split was indepen-
dently associated with the study end points.
The adjusted models included the following baseline variables that
have been associated with 1 study outcome: age, sex, New York
Heart Association class, ischemic etiology, hypertension etiology,
history of atrial fibrillation, history of diabetes, history of chronic
obstructive pulmonary disease, hospitalization in the previous 6
months, body mass index, presence of jugular venous distension,
systolic blood pressure, heart rate, hemoglobin level, pulmonary
congestion on chest radiograph, EF, estimated glomerular filtration
rate, serum albumin, sodium, and neutrophil count. This list includes
all the I-PRESERVE variables included in the recently developed
prognostic models except for the Minnesota Living with Heart
Failure score, which was not collected for a substantial fraction of
the subjects in the present analysis, and a history of myocardial
infarction, which is somewhat redundant with the variable indicating
an ischemic etiology for HF.6
Cox regression analyses of the study outcomes were used to test
for interactions between treatment (irbesartan or placebo) and the
NT-proBNP subgroups. First, the treatment effect (HR) was exam-
ined in each quartile of baseline NT-proBNP. Because the treatment
effect was similar in the 2 lower quartiles and in the 2 upper quartiles
for all end points, the test for interaction using the median split was
believed to be reasonable. Whenever the test for the interaction term
was significant, suggesting that the effect of irbesartan was not the
same in the 2 subgroups defined by the median NT-proBNP, the
effect of irbesartan was examined in each subgroup separately.
Unadjusted Kaplan-Meier curves for the irbesartan and placebo
groups within each NT-proBNP subgroup were compared by the
log-rank test. The baseline characteristics of the irbesartan and
placebo groups were compared within each NT-proBNP subgroup
(Student t test for continuous variables, 2 test of proportions) and
were added to Cox regression analyses of the treatment effect within
each subgroup to help determine whether baseline differences could
explain any observed treatment effects within an NT-proBNP sub-
group. Additional analyses added a set of baseline covariates that
were associated with the baseline NT-proBNP and study end points
and might have confounded the test for interaction.
SPSS version 12.0 (SPSS Inc; Chicago, IL) statistical software
was used for all analyses. A 2-tailed P0.05 was considered
statistically significant without adjustments for making multiple
comparisons in these exploratory analyses.
Results
Association Between Baseline NT-proBNP and
Outcome Events
The NT-proBNP levels at baseline were highly skewed,
ranging from 0 to 28 670 pg/mL with a meanSD of
8691746 pg/mL and median of 339 pg/mL (interquartile
range, 133 to 964 pg/mL). During a mean follow-up of 49.5
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months, 1248 (35.9%) of the 3480 patients with an NT-
proBNP measurement at baseline had a primary end point,
735 (21.1%) died, and 598 (17.2%) had an HF composite
outcome.
Baseline natural logarithm NT-proBNP as a continuous
variable was independently associated with an increased risk
of all end points, even after adjustment for several other
baseline characteristics (Table 1). As reported for septile of
baseline NT-proBNP,6 there was a progressive approximately
linear increase in the logarithm of the HRs across quartiles of
NT-proBNP and in the crude percentage of patients who
experienced each outcome during follow-up (Figure 1, Ta-
ble 1). Collapsing the quartiles above and below the median,
the adjusted risks of the primary end point (HR, 1.79; 95%
CI, 1.56 to 2.10; P0.001), all-cause mortality (HR, 2.04;
95% CI, 1.68 to 2.47; P0.001), and composite of HF events
(HR, 1.77; 95% CI, 1.43 to 2.20; P0.001) were all higher in
patients with above-median NT-proBNP (Table 2).
Interaction Between Baseline NT-proBNP and
Irbesartan Effect
As previously reported, irbesartan had no significant effect on
the primary or secondary outcomes in the entire
I-PRESERVE cohort or in the 8 prespecified subgroups (age,
sex, EF, use of angiotensin-converting enzyme inhibitors, use
of -blockers, diabetes, hospitalization for HF within
6-months, and geographic region) defined by other baseline
characteristics.16 The analysis of interactions with baseline
NT-proBNP concentration, reported in the study, was not
prespecified. Nevertheless, as seen in Table 3, HRs for the
treatment effect in NT-proBNP quartiles 1 and 2 for all
outcomes are similar; hence, these 2 quartiles were combined,
as were quartiles 3 and 4. There was a significant interaction
between the effect of irbesartan and the median split of the
baseline NT-proBNP for the primary outcome (P0.005),
all-cause mortality (P0.05), and the HF composite outcome
(P0.0001) (Table 3). The interaction was due to a beneficial
effect of irbesartan seen in patients below, but not above, the
median NT-proBNP level. In the subgroup with NT-proBNP
below the median, the primary composite outcome occurred
in 24.7% patients in the placebo group and 19.1% in the
irbesartan group (HR, 0.74; 95% CI, 0.60 to 0.90; P0.003);
all-cause mortality occurred in 12.3% patients in the placebo
group and 9.4% in the irbesartan group (HR, 0.75; 95% CI,
0.56 to 0.99; P0.046); and the HF composite outcome
occurred in 11.0% patients in the placebo group and 6.6% in
Table 1. Univariable and Multivariable Analysis of Study End Points by Baseline NT-proBNP as a Continuous
Variable and by Quartile
Events/Patients (% Events) HR (ln HR) 95% CI P
Primary end point
ln NT-proBNP* 1248/3480 (35.9) 1.76 1.68–1.85 0.001
ln NT-proBNP† 1175/3260 (36.0) 1.46 1.37–1.57 0.001
NT-proBNP Q1† 137/831 (16.5) Reference
NT-proBNP Q2† 227/807 (28.1) 1.62 (0.482) 1.31–2.00 0.001
NT-proBNP Q3† 331/814 (40.7) 2.04 (0.713) 1.66–2.52 0.001
NT-proBNP Q4† 480/808 (59.4) 3.05 (1.115) 2.49–3.79 0.001
All-cause mortality
ln NT-proBNP* 735/3480 (21.1) 1.91 1.79–2.03 0.001
ln NT-proBNP† 695/3260 (21.3) 1.57 1.45–1.71 0.001
NT-proBNP Q1† 67/831 (8.1) Reference
NT-proBNP Q2† 113/807 (14.0) 1.55 (0.438) 1.14–2.98 0.005
NT-proBNP Q3† 180/814 (22.1) 2.05 (0.718) 1.53–2.75 0.001
NT-proBNP Q4† 335/808 (41.5) 3.68 (1.303) 2.74–4.95 0.001
HF composite outcome
ln NT-proBNP* 598/3480 (17.2) 1.92 1.79–2.06 0.001
ln NT-proBNP† 561/3260 (17.2) 1.44 1.31–1.58 0.001
NT-proBNP Q1† 42/831 (5.1) Reference
NT-proBNP Q2† 106/807 (13.1) 2.3 (0.833) 1.61–3.30 0.001
NT-proBNP Q3† 158/814 (19.4) 2.62 (0.963) 1.84–3.73 0.001
NT-proBNP Q4† 255/808 (31.6) 3.72 (1.314) 2.59–5.34 0.001
The following baseline variables were included in the multivariable analysis: age, sex, New York Heart Association class, ischemic
etiology, hypertension etiology, history of atrial fibrillation, history of diabetes, history of chronic obstructive pulmonary disease,
hospitalization in the previous 6 months, body mass index, jugular venous distension, systolic blood pressure, heart rate, hemoglobin
level, pulmonary congestion on chest radiograph, ejection fraction, estimated glomerular filtration rate, serum albumin, sodium, and
neutrophil count. HF indicates heart failure; HR, hazard ratio; ln, natural logarithm; NT-proBNP, N-terminal pro-brain natriuretic
peptide; Q, quartile.
*Univariable analysis.
†Multivariable analysis.
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the irbesartan group (HR, 0.57; 95% CI, 0.41 to 0.80;
P0.001). Figure 2 shows the unadjusted time-to-event
curves by treatment group for the time to first primary
outcome, all-cause mortality, and first HF outcome in the
subgroups defined by the NT-proBNP median split. As can be
seen, the beneficial effects of irbesartan were only evident in
the group with NT-proBNP below the median.
Baseline characteristics of patients stratified by NT-
proBNP and assigned treatment were examined to determine
whether the irbesartan effects that were apparent below the
median baseline NT-proBNP might be explained by an
imbalance in the baseline characteristics in the irbesartan and
placebo subgroups (Table 4). There were no significant
differences between the placebo and irbesartan groups below
or above the baseline NT-proBNP level. After adjusting for
20 small, but nonsignificant baseline differences between the
placebo and irbesartan groups (see list in the Data Analysis
section), irbesartan still appeared to have a beneficial effect
on the primary composite outcome (HR, 0.74; 95% CI, 0.60
to 90; P0.003), all-cause mortality (HR, 0.75; 95% CI, 0.56
to 0.99; P0.046), and the HF composite outcome (HR, 0.57;
95% CI, 0.41 to 0.80; P0.001) in the group below the
median NT-proBNP.
Some differences were observed between patients who fell
above or below the median NT-proBNP (Table 4), particu-
larly in the prevalence of atrial fibrillation and in median
estimated glomerular filtration rate that were previously
shown to be correlated with the NT-proBNP levels. When the
test for interaction was repeated to include either or both of
these variables as covariates, the interaction between treat-
ment and NT-proBNP remained significant for all end points.
Discussion
Previous studies have found that natriuretic peptide levels are
elevated in patients with HFrEF and independently correlated
with mortality and morbidity.1,2 Therefore, some have sug-
gested that these biomarkers should be used to select patients
at higher risk for enrollment in clinical trials. In patients with
HFpEF, although natriuretic peptide levels also are in-
creased,3–6,17,20,21 the relationship with outcomes has been
studied prospectively in only a few cohorts.3 Furthermore,
whether patients with higher levels of natriuretic peptides,
and hence risk, are more likely to benefit from treatments has
not been reported. The results of this secondary analysis of
data collected for the I-PRESERVE, a large cohort of
well-characterized patients with HFpEF, confirm that plasma
NT-proBNP concentrations are independently associated
with higher rates of all-cause mortality alone or as a compos-
ite with cardiovascular hospitalizations.6
Table 2. Relative HR and 95% CI of Primary End Point, All-Cause Mortality, HF Composite Event (Sudden
Death and HF Deaths) in Relation to Baseline NT-proBNP Median (339 pg/mL)
Events/Patients (% Events) HR 95% CI P
Primary end point
Baseline NT-proBNP median 1248/3480 (35.9) 2.83 2.51–3.20 0.001
Baseline NT-proBNPcovariates* 1175/3260 (36) 1.79 1.56–2.10 0.001
All-cause mortality
Baseline NT-proBNP median 735/3480 (21.1) 3.31 2.80–3.90 0.001
Baseline NT-proBNPcovariates* 695/3259 (21.3) 2.04 1.68–2.47 0.001
HF composite event
Baseline NT-proBNP median 598/3480 (17.2) 3.44 2.86–4.13 0.001
Baseline NT-proBNPcovariates* 561/3260 (17.2) 1.77 1.43–2.20 0.001
Abbreviations as in Table 1.
*Adjusted for covariates listed in Table 1.
Figure 1. Crude event rates for the primary composite outcome
(A), all-cause mortality (B), and HF composite outcome (C) by
quartile of baseline NT-proBNP. HF indicates heart failure;
NT-proBNP, N-terminal pro-brain natriuretic peptide.
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Perhaps the most interesting and unexpected finding of the
present study is that it does not support the notion that the
benefits of treatment with an angiotensin II receptor blocker
are more likely to be detected in patients with higher levels of
NT-proBNP. The present data do not allow us to address the
possible mechanisms underlying this finding. Perhaps pa-
tients with HFpEF and higher levels of NT-proBNP have
advanced structural disease that is not amenable to this
pharmaceutical intervention. In a study of 119 patients with
Doppler echocardiographically confirmed diastolic dysfunc-
tion, the highest levels of BNP were seen in patients with
worse LV diastolic function and more restrictive filling.21
Likewise, in a small study of 181 patients, the median
NT-proBNP in patients with normal or mild diastolic dys-
function (n109) was 376 pg/mL compared with 1419
pg/mL in patients with moderate to severe diastolic dysfunc-
tion (n72).22 Therefore, if advanced diastolic dysfunction
with restrictive filling represents a structurally irreversible
stage in the natural history of HFpEF, therapy may be less
beneficial in such patients. However, because the
I-PRESERVE enrollment criteria did not include Doppler
echocardiographic measurements for inclusion into the study,
we do not have data to support this hypothesis. Furthermore,
patients with higher levels of NT-proBNP have other risk
factors, such as atrial fibrillation and worse renal function,
that may be less amenable or even aggravated by a particular
treatment. However, adjusting for these types of differences
did not explain the observed interaction.
The findings of this post hoc analysis should not be
extrapolated to HFrEF or other forms of treatment for
HFpEF. They may only apply to patients treated with angio-
tensin receptor blockers in the early stages of HFpEF.
Prospectively designed studies are needed to confirm this
finding and provide more insights into the observed interac-
Table 3. Event Rates and Adjusted* Relative HR of the Primary End Point, All-Cause Mortality, and HF
Outcomes by Quartile and Median Baseline NT-proBNP Patient Subgroups
Cox Model
Placebo Irbesartan HR 95% CI P
Quartile analysis
Primary end point
Q1 82/452 (18.1) 61/418 (14.6) 0.78 0.561–1.089 0.146
Q2 141/451 (31.3) 98/416 (23.6) 0.71 0.545–0.912 0.008
Q3 167/427 (39.1) 186/446 (41.7) 1.054 0.856–1.299 0.619
Q4 248/427 (58.1) 265/443 (59.8) 1.058 0.890–1.259 0.521
All-cause mortality
Q1 37/452 (8.2) 32/418 (7.7) 0.92 0.571–1.472 0.72
Q2 74/451 (16.4) 46/416 (11.1) 0.65 0.449–0.937 0.021
Q3 90/427 (21.1) 101/446 (22.6) 1.046 0.787–1.389 0.758
Q4 171/427 (40) 184/443 (41.5) 1.037 0.842–1.278 0.0729
HF composite outcomes
Q1 27/452 (6) 18/418 (4.3) 0.7 0.388–1.280 0.25
Q2 72/451 (16) 37/416 (8.9) 0.52 0.346–0.765 0.001
Q3 75/427 (17.6) 93/446 (20.9) 1.18 0.871–1.6 0.285
Q4 129/427 (30.2) 147/443 (33.2) 1.11 0.877–1.408 0.381
Median analysis
Primary end point
NT-proBNP 339 pg/mL 223/903 (24.7) 159/834 (19.1) 0.74 0.60–0.90 0.003
NT-proBNP 339 pg/mL 415/854 (48.6) 451/889 (50.7) 1.05 0.92–1.20 0.47
0.005†
All-cause mortality
NT-proBNP 339 pg/mL 111/903 (12.3) 78/834 (9.4) 0.75 0.56–0.99 0.046
NT-proBNP 339 pg/mL 261/854 (30.6) 285/889 (32.1) 1.03 0.87–1.22 0.71
0.05†
HF composite outcomes
NT-proBNP 339 pg/mL 99/903 (11) 55/834 (6.6) 0.57 0.41–0.80 0.001
NT-proBNP 339 pg/mL 204/854 (23.7) 240/889 (27) 1.13 0.94–1.37 0.19
0.0001†
Data are presented as no. events/no. patients (%), unless otherwise indicated. Abbreviations as in Table 1.
*Adjusted for covariates listed in Table 1.
†P for interaction.
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tion between the effect of irbesartan or other treatments and
NT-proBNP in patients with HFpEF. We are not aware of any
other analyses to determine whether the effects of an angio-
tensin II receptor blocker depend on the circulating levels of
NT-proBNP in patients with HFpEF. However, in PEP-CHF
(Perindopril in Elderly People with Chronic Heart Failure)
trial, there was a nonsignificant interaction between the
angiotensin-converting enzyme inhibitor perindopril and NT-
proBNP that appeared to be in the opposite direction of the
present study.14 Even in HFrEF, only 1 study (Australia-New
Zealand Carvedilol Heart Failure Trial)12 has shown a signif-
icantly greater treatment effect in higher-risk patients with
above-median baseline BNP, whereas no significant interac-
tion was found between NT-proBNP and treatment (P0.93)
in COPERNICUS (Carvedilol Prospective Randomized Cu-
mulative Survival).13 In contrast, in the CORONA trial that
Figure 2. Kaplan-Meier curves for time to primary
composite outcome (A), all-cause mortality (B),
and HF composite outcome (C) in groups above
and below the median baseline NT-proBNP.
Abbreviations as in Figure 1.
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investigated the effect of rosuvastatin in patients with mod-
erate to severe HFrEF, a significant treatment interaction with
NT-proBNP was observed.15 Rosuvastatin had no effect on
the primary end point (CV mortality, nonfatal myocardial
infarction, and nonfatal stroke) in the overall cohort but
improved outcomes in patients in the lowest tertile of NT-
proBNP (868 pg/mL). This was consistent with observa-
tions in 20 000 patients with a broad range of severity of
Table 4. Baseline Characteristics in 3480 Patients by NT-proBNP Median and Treatment
NT-proBNP Below Median (n1737) NT-proBNP Above Median (n1737)
Placebo Irbesartan P Placebo Irbesartan P
Age, y 706.5 706.4 0.96 747.1 736.9 0.11
Male sex 37 34.3 0.24 41 46.7 0.02
White race 93.6 93.2 0.62 93.9 94.4 0.83
NYHA class IIIIV vs III 81.1 82.6 0.40 76.8 77.8 0.6
Ischemic etiology 20.6 21.5 0.68 28.1 31.5 0.04
Hypertension etiology 71.4 71.6 0.94 55.6 56.2 0.79
History
Hospitalization in previous 6 mo 32.8 34.2 0.54 54.9 51.5 0.16
Angina pectoris 40 39.7 0.90 41.5 44.2 0.47
Myocardial infarction 18.2 18.9 0.68 29.2 30.1 0.65
Atrial fibrillation 12.2 11.2 0.50 47.7 44.8 0.23
Diabetes mellitus 25.9 24.3 0.45 29.4 30.9 0.48
Valvular disease 6.4 6.2 0.87 15.3 14.8 0.77
Stroke or TIA 7.8 8.6 0.50 11.2 10.8 0.77
COPD or asthma 8.5 6.1 0.06 9.3 12.4 0.04
Anemia at baseline 8.2 8.4 0.98 17.1 16.5 0.56
Body mass index, kg/m2 30.25.1 30.25.3 0.97 28.85.1 29.25.1 0.16
Systolic BP, mm Hg 13614 13814 0.03 13615 13615 0.92
Diastolic BP, mm Hg 808 798 0.78 789.4 799.3 0.70
Heart rate, beats/min 719 719 0.81 7211 7211 0.31
ECG, CXR, and echocardiography variables
LBBB 6.9 7.7 0.52 9.6 9.7 0.96
LV hypertrophy 29 29 0.99 31 31 0.95
Pulmonary congestion CXR 31.2 34.3 0.18 49.1 46.8 0.35
LVEF 618.7 618.9 0.13 58.59.2 57.69.3 0.052
Clinical chemistry
Albumin, g/dL 4.281.4 4.241.4 0.6 4.750.2.0 4.770.1.8 0.81
Sodium, mmol/L 1403 1403 0.91 1393 1393 0.87
Potassium, mmol/L 40.5 40.4 0.46 4.00.49 4.00.5 0.45
Hemoglobin, g/dL 141.9 141.9 0.64 142.0 141.9 0.11
Neutrophil count, 1000 cells/L 4.21.5 4.21.4 0.57 4.82.1 0.82
eGFR, mL/min per 1.73 m2 7822 7821 0.98 6721 6722 0.87
NT-proBNP, pg/mL 14988 14788 0.45 15732147 16032338 0.79
Medications
ACE inhibitor 22 23 0.56 28 29 0.52
-blocker 58 56. 0.49 60 64 0.09
Calcium channel blocker 45 46 0.59 34 37 0.33
Digitalis 5.1 5.2 0.94 22 22 0.85
Diuretic 79 78 0.68 88 86 0.29
Spironolactone 12 12 0.99 20 19 0.34
Aspirin 56 60 0.06 52 55 0.28
Lipid-lowering agents 30 34 0.06 28 31 0.14
Data are presented as meanSD or %. ACE indicates angiotensin-converting enzyme; BP, blood pressure; COPD, chronic obstructive pulmonary
disease; CXR, chest radiograph; eGFR, estimated glomerular filtration rate; LBBB, left bundle branch block; LV, left ventricular; LVEF, LV ejection
fraction; NYHA, New York Heart Association; TIA, transient ischemic attack. Other abbreviation as in Table 1.
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cardiovascular disease who had NT-proBNP measured in the
Heart Protection Study.23 Thus, although measurement of
natriuretic peptide levels remains extremely useful in identi-
fying patients with a cardiac cause of their symptoms,
particularly those with HFpEF where diagnosis of diastolic
dysfunction may be difficult using Doppler echocardiograp-
hic criteria, the assumption is that treatments are always more
likely to benefit patients with higher baseline levels of
natriuretic peptides and risk, should be carefully examined
before using levels of natriuretic peptides to select patients
for clinical trials.
Another interesting finding is that the nature of the rela-
tionship between mortality and the logarithm of NT-proBNP
levels in the present study is similar to that reported in studies
of HFrEF with similar severity of HF, even though the
baseline levels of NT-proBNP tend to be 2 to 4 times greater
in HFrEF.2,15,17,20,24 For example, the median NT-proBNP of
339 pg/mL in the present study is similar to the median value
of 409 pg/mL seen in the PEP-CHF trial, which randomized
similar patients with HFpEF to the angiotensin-converting
enzyme inhibitor perindopril.15 In contrast, in the Valsartan
Heart Failure Trial, the median baseline NT-proBNP was 903
pg/mL, and the natural logarithm of NT-proBNP was asso-
ciated with an adjusted HR for all-cause mortality of 1.5
(95% CI, 1.3 to 1.6), similar to the HR of 1.6 (95% CI, 1.5 to
1.7) found in the present analysis. The difference in NT-
proBNP levels between HFrEF and HFpEF may be related to
lower LV diastolic wall stress in HFpEF due to smaller LV
volumes and thicker LV walls that would be expected to
produce smaller increases in natriuretic peptides.25 Hence,
despite the potential differences in the levels and mechanisms
for the increase in natriuretic peptides in HFrEF and HFpEF,
the prognostic information provided by NT-proBNP appears
to be similar in the 2 types of HF and consistent with an
overall linear relationship between the logarithms of the HRs
and NT-proBNP.
A major limitation of this secondary analysis of data from
I-PRESERVE is that the findings might be spurious and need
to be confirmed in other samples. Furthermore, we used a
somewhat arbitrary and retrospective level of NT-proBNP to
classify patients into different risk groups and to test for the
interaction. Additional studies are needed to confirm our
results and find the best threshold to identify patients who
benefit. Nevertheless, the present results suggest that one
should not assume that patients at higher risk are always more
likely to benefit from a treatment. However, the effect of
treatment on absolute benefit may be small in patients already
at low risk.
In conclusion, levels of NT-proBNP are elevated in HFpEF
but to a lesser extent than in HFrEF. However, the prognostic
information provided by NT-proBNP appears to be similar in
the 2 types of HF. In this post hoc analysis of I-PRESERVE
data, the use of irbesartan was associated with improved
outcomes only in patients with HFpEF without substantially
elevated NT-proBNP. This apparent benefit of irbesartan in
lower-risk patients with HFpEF may indicate an effect of the
drug earlier, but not later, in the natural history of the disease
when structural changes might not be responsive to a thera-
peutic intervention. The strategy of using elevated plasma
concentrations of natriuretic peptides as a patient selection
criterion in trials of HFpEF should be reconsidered in the
light of these results, which may help to set appropriate
thresholds or abandon them all together.
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CLINICAL PERSPECTIVE
Natriuretic peptides are independent predictors of adverse outcomes in patients with heart failure (HF) and reduced ejection
fraction, but data to support their role in HF and preserved ejection fraction are limited. Several recent HF trials have
excluded patients with low natriuretic peptide levels to increase the likelihood of including patients with more severe HF
and to increase the number of outcome events. This approach also assumes that the study intervention will have a greater
effect in higher-risk patients, but this presumption is not well established. We tested this hypothesis in a post hoc analysis
of 3480 patients in the I-PRESERVE (Irbesartan in Heart Failure with Preserved Ejection Fraction Trial) who had a
baseline measurement of N-terminal pro-brain natriuretic peptide (NT-proBNP). Baseline NT-proBNP level was
independently associated with an increased risk of all end points measured. Overall, irbesartan had no effect of any of the
outcomes; however, its use was associated with improved outcomes in patients with NT-proBNP levels below, but not
above, the median. After adjusting for 20 baseline covariates, irbesartan still had a beneficial effect on the primary outcome
(hazard ratio, 0.74; 95% CI, 0.60 to 90; P0.003), all-cause mortality (hazard ratio, 0.75; 95% CI, 0.56 to 0.99; P0.046),
and HF composite outcome (hazard ratio, 0.57; 95% CI, 0.41 to 0.80; P0.001) in patients with NT-proBNP below the
median. These findings may indicate a beneficial effect of irbesartan on early, but not later, high-risk stages of the disease
and question the strategy of using elevated natriuretic peptide level as a patient selection criterion in HF with preserved
ejection fraction trials. More studies are needed to support or contest this practice.
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